These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 19679052)

  • 1. Immunohistochemical analysis of selected molecular markers in esophagus precancerous, adenocarcinoma and squamous cell carcinoma in Iranian subjects.
    Allameh A; Rasmi Y; Nasseri-Moghaddam S; Tavangar SM; Sharifi R; Sadreddini M
    Cancer Epidemiol; 2009 Jul; 33(1):79-84. PubMed ID: 19679052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
    Chatelain D; Fléjou JF
    Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus.
    Hanas JS; Lerner MR; Lightfoot SA; Raczkowski C; Kastens DJ; Brackett DJ; Postier RG
    Cancer; 1999 Sep; 86(5):756-63. PubMed ID: 10463972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of the risk of adenocarcinoma in Barrett's esophagus by means of tumor markers (p53 and Ki67).
    Trakál E; Guidi A; Butti AL; Trakál JJ; Sambuelli R; Zárate FE
    Acta Gastroenterol Latinoam; 2010 Sep; 40(3):211-5. PubMed ID: 21049770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paget cells in the esophagus: assessment of their histopathologic features and near-universal association with underlying esophageal adenocarcinoma.
    Abraham SC; Wang H; Wang KK; Wu TT
    Am J Surg Pathol; 2008 Jul; 32(7):1068-74. PubMed ID: 18496141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ki-67 and ProExC are useful immunohistochemical markers in esophageal squamous intraepithelial neoplasia.
    Wang WC; Wu TT; Chandan VS; Lohse CM; Zhang L
    Hum Pathol; 2011 Oct; 42(10):1430-7. PubMed ID: 21420715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
    O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
    Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolomics study of esophageal adenocarcinoma.
    Zhang J; Liu L; Wei S; Nagana Gowda GA; Hammoud Z; Kesler KA; Raftery D
    J Thorac Cardiovasc Surg; 2011 Feb; 141(2):469-75, 475.e1-4. PubMed ID: 20880550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology and molecular biology of Barrett esophagus.
    Casson AG; Williams L; Guernsey DL
    Semin Thorac Cardiovasc Surg; 2005; 17(4):284-91. PubMed ID: 16428034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topological analysis of p21WAF1/CIP1 expression in esophageal squamous dysplasia.
    Shirakawa Y; Naomoto Y; Kimura M; Kawashima R; Yamatsuji T; Tamaki T; Hamada M; Haisa M; Tanaka N
    Clin Cancer Res; 2000 Feb; 6(2):541-50. PubMed ID: 10690537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders.
    Glickman JN; Yang A; Shahsafaei A; McKeon F; Odze RD
    Hum Pathol; 2001 Nov; 32(11):1157-65. PubMed ID: 11727253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Collision carcinoma of the residual cervical esophagus 27 years after esophageal cancer surgery.
    Naritaka Y; Ogawa K; Shimakawa T; Wagatsuma Y; Isohata N; Asaka S; Miyaki A; Shiozawa S; Katsube T; Yoshimatsu K; Aiba M; Ide H
    Anticancer Res; 2007; 27(1B):505-11. PubMed ID: 17348434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E2F-1 overexpression correlates with decreased proliferation and better prognosis in adenocarcinomas of Barrett oesophagus.
    Evangelou K; Kotsinas A; Mariolis-Sapsakos T; Giannopoulos A; Tsantoulis PK; Constantinides C; Troupis TG; Salmas M; Kyroudis A; Kittas C; Gorgoulis VG
    J Clin Pathol; 2008 May; 61(5):601-5. PubMed ID: 17908803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear translocation of glutathione transferase omega is a progression marker in Barrett's esophagus.
    Piaggi S; Marchi S; Ciancia E; Debortoli N; Lazzarotti A; Saviozzi M; Raggi C; Fierabracci V; Visvikis A; Bisgaard HC; Casini AF; Paolicchi A
    Oncol Rep; 2009 Feb; 21(2):283-7. PubMed ID: 19148497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Barrett esophagus: current state of the problem].
    Belova GV; Sokolov VV; Budzinskiĭ AA; Mel'chenko DS
    Eksp Klin Gastroenterol; 2007; (3):36-44. PubMed ID: 17937004
    [No Abstract]   [Full Text] [Related]  

  • 17. E-cadherin expression in gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma: an immunohistochemical and immunoblot study.
    Swami S; Kumble S; Triadafilopoulos G
    Am J Gastroenterol; 1995 Oct; 90(10):1808-13. PubMed ID: 7572899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of glutathione s-transferase pi in benign mucosa, Barrett's metaplasia, and adenocarcinoma of the esophagus.
    Chandra RK; Bentz BG; Haines GK; Robinson AM; Radosevich JA
    Head Neck; 2002 Jun; 24(6):575-81. PubMed ID: 12112555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of cyclin E in dysplasia, carcinoma, and nonmalignant lesions of Barrett esophagus.
    Sarbia M; Bektas N; Müller W; Heep H; Borchard F; Gabbert HE
    Cancer; 1999 Dec; 86(12):2597-601. PubMed ID: 10594854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expressions of cyclin-dependent kinase inhibitors (p27 and p21) and their relation to p53 and Ki-67 in oral squamous tumorigenesis.
    Choi HR; Tucker SA; Huang Z; Gillenwater AM; Luna MA; Batsakis JG; El-Naggar AK
    Int J Oncol; 2003 Feb; 22(2):409-14. PubMed ID: 12527941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.